| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.9 | 1.0 |
| Gross profit | 1.2 | 0.6 |
| Net income | -0.4 | -0.5 |
| EPS (diluted, $ a share) | $-0.01 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +80.8% |
|---|---|
| Gross margin | 63.9% |
| Operating margin | -20.1% |
10-Q filed with the SEC, OTC: AURX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nuo Therapeutics, Inc.: key numbers
- Share price
- $1.09Close, Nov 13
- Market cap
- $53M
- Shares outstanding
- 48.59MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nuo Therapeutics, Inc.
All →Nuo Therapeutics Financial Results
Nuo Therapeutics reported Q3 2026 financial results with total revenue of $1.9 million, an 80% increase year-over-year. The company highlighted strong growth in hospital-based Aurix sales and noted that final 2027 Medicare reimbursement rulings reinforce its long-term growth outlook.
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above”
David Jorden, Nuo’s Chief Executive and Financial Officer
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth.”
David Jorden, Nuo’s Chief Executive and Financial Officer
Nuo Therapeutics Debt Financing Update with Scott M. Pittman
Nuo Therapeutics entered into an amendment to its Amended and Restated Loan and Security Agreement to close a second funding tranche of $325,000. The company has now received an aggregate of $2.0 million under the facility, with the new notes bearing 12% interest and maturing on December 31, 2028. The funding involved the joinder of three new lenders and an additional commitment from director Scott M. Pittman.
- Counterparty
- Scott M. Pittman
- Term
- through Dec 2028